Back to results
US 10,519,230 B2Granted
Nucleic acids encoding IL-33 antibodies
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAndrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAndrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
Estimating the term…
The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.
An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof that specifically binds human interleukin-33 (IL-33), wherein the antibody or antigen-binding fragment comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:
An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof that specifically binds human interleukin-33 (IL-33), wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.